Celsion Corporation (NASDAQ:CLSN) has reserved a top momentum style rating from Zacks Research. The momentum rating acts as an important barometer to show as to when a stock will attain a favourable position, …
Stock market analysts and brokers have recently amended their target prices on shares of Celsion Corporation (CLSN). According to the latest research reports released, 1 analyst has issued a rating of “buy”, 1 analysts …
Stock market analysts watching Celsion Corporation (CLSN) have recently changed their ratings on the stock. The latest reports which are outstanding on Sunday 29th of January state 1 analyst has a rating of “strong …
Street analysts and crowd investors have recently weighed in on shares of Celsion Corporation (NASDAQ:CLSN). Research provided by Beta Systems monitors crowd sourced sentiment and provides consensus stock
According to the latest SEC filings, insiders at Celsion Corporation (NASDAQ:CLSN) have increased their position in the stock by 14.33% over the past 6 months. Insiders now own 1.00% of total outstanding shares. There are …
NASDAQ
Director Robert W. Hooper bought 10,000 shares of CLSN stock on 09/10/2012 at the average price of $4.95. Robert W. Hooper owns at least 78,427 shares after this. The price of the stock has increased by 17.37% …
Not open for further replies. I wanted to buy a stock, I looked it up and it is traded on the NASDAQ - Celsion Corp (CLSN). The symbol is valid, and shows up in the drop down when I start to search. When I click on the Get …
Posttraumatic stress disorder
Shares of Celsion Corp. (NASDAQ:CLSN) traded down 1.57% during trading on Wednesday, hitting $0.97. The stock had a trading volume of 103,680 shares. The stock’s 50 day moving average is $1.17 and its 200 day …
Celsion Corporation (NASDAQ:CLSN), a clinical stage oncology drug development company ... Register now to create your own custom streaming stock watchlist. NYSE, AMEX, and ASX quotes are delayed by at least 20 …
Celsion Corp. CLSN agreed to sell $8.6 million of common stock and warrants to institutional investors and certain Celsion officers and directors. The cancer drug company is selling 3.22 million units for which …